Pharmaceutical

NNC-05600004 by Novo Nordisk for Liver Diseases: Likelihood of Approval

NNC-05600004 is under clinical development by Novo Nordisk and currently in Phase I for Liver Diseases.

Dec 20, 2023 - 18:00
NNC-05600004 is under clinical development by Novo Nordisk and currently in Phase I for Liver Diseases.
Read the original article

Tags:

Previous Article

Meloxicam fast acting by Viatris for Post-Operative Pain: Likelihood of Approval

Next Article

FLU-SV-mRNA by Curevac for Influenza A Virus, H1N1 Subtype Infections: Likelihoo...

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Sensorion raises $16m for gene therapies to treat deafness

Sensorion raises $16m for gene therapies to treat deafness

Apr 9, 2024

STAT+: BrainStorm’s case for ALS approval relies on ‘grossly deficient’ data, FDA finds

STAT+: BrainStorm’s case for ALS approval relies on ‘gr...

Sep 26, 2023

AstraZeneca scores its second paediatric approval for Soliris in Japan

AstraZeneca scores its second paediatric approval for S...

Aug 26, 2023